Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $33 million versus the consensus estimate of $29.98 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance